pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,026 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1786Endpoints1391Fierce Biotech710BioSpace702BioPharma Dive526raps234onclive165fda recalls113
therapy area
allOncology12335Rare Disease3228Immunology2872Cardiology2752Hematology2179Pulmonology2149Vaccines
  • cAMPfield Therapeutics raises $180 million to develop oral IBD drug prifemilast
    cAMPfield Therapeutics, a California biotech, announced a $180 million Series A financing to advance its oral anti‑inflammatory candidate for inflammatory bowel disease. The investigational drug,…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • Novo Nordisk invests $380M to expand manufacturing in Czech Republic and China, while Cellares raises $50M Series D
    Novo Nordisk announced a significant investment to broaden its manufacturing footprint in both China and the Czech Republic. In the Czech Republic, the company is allocating roughly $380 million t…
    Endpoints · 4mo agoDealPositive↗ source
← prev
page 94 of 122
next →
fda medwatch111
globenewswire health73
fda press59
1802
Psychiatry & CNS1204
Ophthalmology1062
Pain778
Endocrinology & Metabolism777
Nephrology762
  • Medicare $2,000 out-of-pocket cap boosts use of high-cost drugs, study shows
    A recent study published in JAMA Health Forum examined how the Inflation Reduction Act’s $2,000 annual out-of-pocket limit for Medicare beneficiaries affected drug consumption. The analysis found…
    Endpoints · 4mo agoRegulatoryPositive↗ source
  • FDA advisory panel unanimously backs Moderna’s flu vaccine
    The FDA’s Vaccines and Related Biological Products Advisory Committee voted unanimously to recommend Moderna’s seasonal influenza vaccine. The vote overturns earlier hesitations from previous agen…
    Endpoints · 4mo agoRegulatoryPositive↗ source
  • U.S. Treasury Considers New Screening Rules for Investments in Chinese Biotech
    Treasury Department officials are reviewing possible measures to screen U.S. capital flowing into Chinese biotechnology firms, according to multiple sources familiar with the discussions. The revi…
    Endpoints · 4mo agoRegulatoryNegative↗ source
  • Biogen to acquire RayThera in up to $1 billion deal for immunology pipeline
    Biogen announced it will acquire RayThera, a startup founded in 2023, in a deal valued at up to $1 billion. The acquisition gives Biogen access to RayThera’s immunology pipeline, which includes th…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • Pfizer CFO Dave Denton to leave; Denali Therapeutics sells $195 million FDA priority review voucher
    Pfizer announced that its chief financial officer Dave Denton will depart on Aug. 15 to take a role outside the pharmaceutical sector. He has been CFO since May 2022. In the interim, finance chief…
    BioPharma Dive · 4mo agoDealNeutral↗ source
  • Pfizer CFO to leave in August as GSK secures approval for urinary-tract infection drug
    Pfizer announced that its chief financial officer, Dave Denton, will step down in August, ending his tenure at the company. GSK reported that it has received regulatory approval for a new treatmen…
    Endpoints · 4mo agoRegulatoryNeutral↗ source
  • Novocure's electric field therapy fails Phase 3 glioblastoma trial, not extending patient survival
    Novocure announced on Thursday that its electric fields device, used together with standard chemoradiation, did not improve overall survival for patients with glioblastoma in a Phase 3 trial. The…
    Endpoints · 4mo agoNegative readoutNegative↗ source
  • Moderna appoints Ester Banque as chief commercial officer and expands Stephen Hoge's responsibilities
    Moderna announced a leadership reshuffle as it readies for upcoming product launches. The company named Ester Banque, who previously led U.S. operations at animal health firm Zoetis, as its new ch…
    Endpoints · 4mo agoNeutral↗ source
  • Eli Lilly's TuneLab AI platform reaches 100 members and integrates Chai's models
    Eli Lilly has built TuneLab, an AI initiative that gives biotech companies free access to a range of artificial‑intelligence tools to support drug discovery and development. The program recently a…
    Endpoints · 4mo agoPositive↗ source
  • F2G and Shionogi report positive Phase 3 results for antifungal candidate olorofim
    F2G and Shionogi announced that their joint antifungal candidate, olorofim, met the primary endpoints in a Phase 3 trial. The data were released Thursday morning and showed the drug performed compa…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • Cardiovascular biotech Kardigan raises $400M in IPO, fourth 2026 $400M+ offering
    Kardigan, a cardiovascular drug startup, priced a $400 million initial public offering on Wednesday, adding to a recent surge in large biotech offerings. The company becomes the fourth biotech in…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • Kardigan secures $400 million IPO to fund three clinical-stage cardiovascular candidates
    Kardigan, a New Jersey biotech focused on heart disease, announced it raised $400 million in a Nasdaq initial public offering. The capital will be directed toward advancing three clinical-stage dr…
    Endpoints · 4mo agoDealPositive↗ source
  • Biogen to acquire San Diego biotech RayThera in up to $1 billion deal
    Biogen announced it will acquire RayThera, a San Diego-based biotech, in a transaction valued at up to $1 billion. The agreement specifies that most of the payment will be made through milestone-b…
    Endpoints · 4mo agoDealPositive↗ source
  • RA Capital, Forbion and Sanofi Ventures back Korean eye-drug startup
    RA Capital, Forbion and Sanofi Ventures are reported to be providing financing for a new eye-drug company that is developing its product in Korea. The investment follows a growing pattern where la…
    Endpoints · 4mo agoDealNeutral↗ source
  • Innoviva revives Lyndra's long-acting oral drug platform
    Innoviva, a healthcare asset and royalties holding firm, announced it is bringing back Lyndra's long-acting oral drug delivery platform. The technology, which previously attracted more than $380 mi…
    Endpoints · 4mo agoPositive↗ source
  • Industry eyes revenue potential of next‑generation peptide drugs beyond GLP‑1
    The article notes that just a few years ago analysts were busy estimating the market size for GLP‑1 based weight‑loss medicines. Today the conversation has shifted toward the commercial possibilit…
    Endpoints · 4mo agoNeutral↗ source
  • UK waitlist for Novo Nordisk’s Wegovy reaches 30,000 a week, tripling after approval
    Novo Nordisk’s weight‑loss injection Wegovy has been approved in the United Kingdom. Within a week of the green light, a major online pharmacy reported that its waiting list surged to roughly 30,00…
    Endpoints · 4mo agoApprovalPositive↗ source
  • Jazz Pharmaceuticals partners with AbCellera on T-cell engager program targeting GI cancers, deal up to $4.1 billion
    Jazz Pharmaceuticals announced a new collaboration with Canadian antibody company AbCellera to develop T-cell engager therapies aimed at gastrointestinal cancers. The agreement could be worth as m…
    Endpoints · 4mo agoDealPositive↗ source
  • Spot Bio raises $40M to begin mRNA therapy trials for Duchenne muscular dystrophy
    Spot Bio, a biotech startup operating in California and China, has started preclinical testing of a genetic medicine aimed at restoring the missing protein dystrophin in patients with Duchenne musc…
    Endpoints · 4mo agoDealPositive↗ source
  • Biopharma manufacturers turn to flexible, modular facilities to meet diverse therapy demands
    Biopharma development is increasingly focused on specialized and personalized treatments such as cell and gene therapies, antibody-drug conjugates and monoclonal antibodies. At the same time, the m…
    Fierce Biotech · 4mo agoPositive↗ source
  • FDA signals new window for companies with recent complete response letters after commissioner’s exit
    After FDA Commissioner Marty Makary left, the agency indicated it will reconsider drugs that received complete response letters in the past year. The move offers sponsors a chance to resubmit thei…
    Endpoints · 4mo agoRegulatoryPositive↗ source
  • FDA issues warning letters to 25 telehealth firms over misleading compounded GLP-1 marketing
    The U.S. Food and Drug Administration has sent warning letters to 25 telehealth companies. The letters cite concerns about how the firms promote compounded GLP-1 drugs used for weight loss. The ag…
    Endpoints · 4mo agoRegulatoryNegative↗ source
  • UniQure plans to file Huntington’s disease gene therapy with FDA after leadership shift eases data requirements
    UniQure, a Dutch biotech, announced it will seek FDA approval for its gene therapy targeting Huntington’s disease later this summer. The company said FDA staff indicated that three years of data f…
    BioPharma Dive · 4mo agoRegulatoryNeutral↗ source